Using nanoparticles to tell apart pancreatic cancer from benign pancreatic conditions
Distinguishing Pancreatic Cancer from Benign Pancreatic Disease using Nanoparticle-based Biomarkers
This study is working on a simple blood test that uses tiny particles from tumors to help tell the difference between pancreatic cancer and non-cancerous pancreatic issues, making it easier and safer to detect cancer early without needing risky procedures like biopsies.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11001197 on NIH RePORTER |
What this research studies
This research focuses on developing a blood test that utilizes nanoparticles derived from tumors to differentiate between pancreatic cancer and benign pancreatic diseases. By employing advanced technology, the study aims to extract and analyze these nanoparticles from small blood samples, which is crucial for early detection of pancreatic cancer. This approach seeks to reduce the need for invasive procedures like biopsies, which carry risks and costs. The ultimate goal is to create a reliable biomarker panel that can be used in clinical settings for better patient management.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with pancreatic cysts or those at risk for pancreatic cancer.
Not a fit: Patients who have already been diagnosed with advanced pancreatic cancer or those without pancreatic conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a non-invasive blood test that accurately identifies pancreatic cancer, improving early detection and treatment outcomes for patients.
How similar studies have performed: Other research has shown promise in using biomarker panels for cancer detection, suggesting that this approach could be effective.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Ibsen, Stuart Duncan — Oregon Health & Science University
- Study coordinator: Ibsen, Stuart Duncan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.